Key result
The structure-guided activator CLM142 exhibited 10-fold greater potency (EC50 0.19 μM) and higher specificity for the human M-channel compared to retigabine.
Why the study?
Structural mechanisms governing the unique heteromeric assembly and subthreshold gating of the human M-channel have remained unresolved.
Absolute Event Rate: 0.19% vs 2.16%
Cryo-EM structures of the human M-channel reveal its stoichiometric plasticity and subthreshold activation mechanism, enabling the development of CLM142, a highly potent and selective activator.
CLM142 merits further preclinical testing; hypothesis-generating for human translation pending clinical studies.
The M-channel, a heterotetrameric voltage-gated potassium channel formed by KCNQ2 and KCNQ3 subunits, critically regulates neuronal excitability, with dysfunction linked to epilepsy and developmental encephalopathies. Despite its physiological importance, structural mechanisms governing its unique heteromeric assembly and subthreshold gating have remained unresolved. We present cryo-EM structures of human M-channels revealing unprecedented stoichiometric plasticity, with all possible KCNQ2:KCNQ3 configurations (1:3 to 3:1) observed. Electrophysiology of engineered concatemers shows these assemblies recapitulate native function. Structural analyses uncover that KCNQ3’s voltage-sensing domain (VSD) adopts a more depolarized conformation than KCNQ2, explaining its signature subthreshold activation. Leveraging these insights, we developed CLM142, a structure-guided activator with 10-fold greater potency and specificity than withdrawn retigabine. CLM142 enabled open-state structure determination, revealing how PIP2 binding couples VSD movement to pore opening. Our work provides an atomic-resolution framework for understanding M-channel’s unique assembly, physiology, disease mechanisms, and targeted therapeutic design.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Neurological disorders (preclinical). CLM142 vs. Retigabine was evaluated on M-channel activation potency (EC50 in μM). The structure-guided activator CLM142 exhibited 10-fold greater potency (EC50 0.19 μM) and higher specificity for the human M-channel compared to retigabine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: